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Abstract 
About 35 million people worldwide were suffered from Alzheimer’s disease (AD) in 2014 and the number of 
patients was expected to increase by 4-fold in 2050. As a neurodegenerative disease impacting our society, 
the pathogenesis and prognosis of AD have not yet fully understood. Senile plaque is generally regarded as 
one of the hallmarks of the disease, which may be due to the imbalance of Aβ peptides in the brain. Over 
the last decades, studies of early onset familial AD have led us to a deeper understanding of the genetics 
and molecular biology of AD. There is increasing evidence to suggest that the pathogenesis of AD is more 
likely to be caused by multiple genetic mutations. However, the precise genetic component leading to AD 
pathogenesis remains unclear. In this review, we will briefly introduce the classification of AD in the context 
of genetics. Then we will discuss the gene mutations in chromosome 21, 19 and presenilin as well as their 
links to Aβ peptides. Imaging data will be discussed alongside to complement the associated structural and 
physiological changes in the brain. It is our hope that future research in genetics will continue to enhance 
our understanding of the pathogenesis of AD and the mechanisms leading to the formation of senile 
plaques.  
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Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disease in which the cognitive decline of the patient 
progresses over time. It is one of the most common diseases of senile dementia symptoms, including 
waning memory, and cognitive dysfunctions, such as time, place, character, emotion, as well as personality 
changes. Severe AD patients could suffer from language obstacles leading to difficulties in daily 
communication. With the continuous improvement of living standard and life-span, the incidence rate of 
AD is rising.  As of 2014, the number of AD patients has reached 35 million. In 2050, the number of AD 
patients will exceed 100 million. Currently, the US has over 5 million AD patients, with an annual cost to 
the healthcare system over $ 200 billion. From now to 2050, the cost of treatment for AD will reach $ 20 
trillion [1]. These represent a significant burden on the nation resource. Clearly, a good understand on the 
pathogenesis and prognosis of AD is very important. 
Classification of Alzheimer’s disease in the context of genetics 
AD can be classified according to the age of the patient, namely age early and late AD. Early onset AD 
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(EOAD) occurs in patients younger than 65 years old, while for the late onset AD (LOAD) the patients are 
older than 65 years. One of the distinct pathological characteristics of AD is the presence of amyloid-β 
plaques in the brain [2]. Regardless of EOAD or LOAD, the pathogenesis is more or less associated with 
genetics. Gatz et al believe more than half (60 % - 80 %) of the AD pathogenesis is influenced by genetics, 
which is referred to as the familial AD (FAD) [3]. Although the etiology and pathogenesis of AD is not 
completely understood, there are clear evidence suggest that gene mutations lead to extracellular 
deposition of amyloid-β (Aβ) and subsequently the formation of senile plaque, which is one of one of the 
characteristic pathological changes in AD [4,5]. These AD disease genes are family associated and mostly 
autosomal dominant, with the FAD gene located on chromosome 21, 19, 14 and 1. On the 21, 14, and 1 
chromosome, the mutations are linked to EOAD. On the 19 chromosome carrying Apolipoprotein E (ApoE), 
the mutations are linked to LOAD [2]. Most of the pathogenesis of AD is not solely determined by a single 
gene. Instead, it is more likely to be caused by multiple genes and environmental factors, together with 
genetic mutation [6,7]. However, the precise genetic component leading to AD pathogenesis remains 
unclear. 
Mechanisms of AD related to Aβ 
Based on the pathological mechanism of Aβ in the formation of senile plaques, this review will explore 
the pathology evidence and functional evidence of AD in the context of genetics. Literature evidence 
suggested that there exists dynamic equilibrium between brain extracellular Aβ generation (production) 
and clearance (clearance). When the balance is upset, Aβ accumulation (accumulation) and aggregation 
(aggregation) begin [8-10]. Neurotoxic Aβ aggregation leads to the formation of plaques of amyloid-β, 
resulting in AD patients with dementia and other cognitive disorders. In addition, we will discuss other 
genetic factors leading to AD pathogenesis and the prevention mechanisms (see Fig. 1). 
 
 
Figure 1. Hypothesis on AD based on mutations associated with Aβ peptides. The rationale behind this 
hypothesis is that genes and gene mutations affect the production, clearance, degradation and aggregation of 
Aβ. These metabolic processes, if not in balance, may lead to cell death, the formation of senile plaques and 
increased AD risk. 
Chromosome 21:  
Formation of Aβ  
Autosomal dominant inheritance AD and/or family EOAD are closely related to the amyloid precursor 
protein (APP) on the chromosome 21. Specifically, the hydrolysis of APP by β-secretase and γ-secretase 
complex leads to the formation of hydrophobic amyloid-β [11]. At the same time, hydrolysis lead to the 
formation of water soluble APP intracellular structure (AICD), which could result in apoptosis. In addition to 
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the production of amyloid-β, APP can be hydrolyzed by the α-secretase enzyme to form 3-kDa product 
(P3), AICD and soluble APP extracellular domain (sAPPα), which has a neuroprotective effect [12,13]. 
Excessive sAPPα can also suppress the formation of toxic Aβ [11]. As shown in Fig. 2, sAPPβ, Aβ and AICD 
are generated in the 671/672 locus of APP via the β-secretase enzyme hydrolysis, while sAPPα, P3 and 
AICD are produced in the 687/688 locus of APP by α-secretase. The formation of Aβ40 (Aβ42) is 
accomplished by hydrolysis of APP with β-secretase through γ40 (γ42) in which γ40 and γ42 are kinds of γ-
secretase (see Fig. 2). Choy R et al reported that Aβ40 is mainly produced in trans-Golgi network (TNG). 
After the detachment of TNG from the nucleus, the APP aggregation in endosomes reduced, so as the 
accumulation of Aβ [13]. In APP transgenic mice, it has been found that the loss of neuronal cysteine 
protease cathepsin B (CatB) led to in increased amyloid plaque load and increased Aβ1-42 to Aβ1-40 ratios. In 
early APP transgenic mice, the expression level of CatB elevated. This leads to the denaturation of Aβ, 
resulting in the inactivation of Aβ oligomers and reduction of Aβ fibers [14].  
APP gene mutations: which one affecting Aβ? 
As shown in Fig. 2, APP is modified by mutation to form toxic Aβ. Accumulation of these toxic peptides 
increases the risk of getting AD. Usually, the mutation occurred at the cleavage site β-secretase enzyme 
(Aβ) near the Swedish KM670 / 671NL. With this mutation, the intracellular Aβ formation is about 6 to 8-
fold more likely than wild type [15]. However, whole-genome sequencing revealed that A673T mutation in 
APP was indeed due to the β site being replaced, which led to the decrease in extracellular Aβ peptides. For 
the elderly people that do not suffer from AD, the knowledge on A673T mutation may offer predictive 
and/or preventive measures for cognitive decline [16].  
 
 
Figure 2. Schematic to show the hydrolysis of APP and the formation of Aβ (APP gene on chromosome 21 
mutation, abnormal hydrolysis to produce toxic Aβ). APP is hydrolyzed into peptide fragments (with Aβ 
marked pink), including soluble sAPPβ, Aβ, AICD or sAPPα, P3 and AICD. The formation of Aβ40 (Aβ42) is 
accomplished by hydrolysis of APP with β-secretase through γ40 (γ42). 
In case of homozygotes, A673V (valine-673) gene mutation increases the generation of Aβ42 and Aβ40 
simultaneously, thereby increasing the accumulation of amyloid fibrils in vitro. However, the same 
mutation shows the opposite effects on Aβ42 and Aβ40 in the heterozygotes [17]. More sAPPα is generated 
via the hydrolysis of APP at allele 690 and 692 by the substitution of alanine and phenylalanine, 
respectively. At the same time, the generation of P3 peptide is reduced, which facilitates the increase of 
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Aβ40 and Aβ42 [18].  For Arctic E693 mutation carriers, the levels of Aβ42 and Aβ40 in plasma are lower than 
that of wild type. Yet, the rate of Aβ generation in the mutants is faster, which may reflect another possible 
disease mechanism associated with AD [19]. At the γ cleavage sites, the A713T mutation can lead to 
cerebral amyloid angiopathy symptoms, which is also associated with AD [20]. 
In Iranian FAD, allele Thr714Ala may induce a remarkable increase in the Aβ1-42 / Aβ1-40 ratio (up to 11 
times) [21].  Recently, Sieczkowski E found that I716F βAPP is a mutation associated with glutamate-Aβ, 
which increases the generation of senile plaques and nerve tangles [22].  The APP 717 mutation increases 
the production of the soluble βAPP, Aβ42 and Aβ38, which are associated with dementia [23-25]. The 
newly discovered K724 mutation in China (40-58 years old) has been shown to enhance the Aβ1-42 / Aβ1-40 
ratio (over 2-fold). Monitoring this mutation may provide preventive measures for early-onset FAD in China 
[26]. Another mutation K16N, which is situated at the α hydrolysis sites, may provide information on early-
onset AD risk.  K16N affects the APP alleles and the formation of longer Aβ peptides (e.g. from Aβ40 to 
Aβ42). Although the Aβ peptide itself does not show cytotoxic effects, equimolecular mixture of both wild 
type Aβ and mutant type Aβ is far more toxic. In addition, K16N inactivates the Aβ-degrading enzyme, 
neprilysin, affecting the elimination of Aβ42 peptide [27]. The D7H mutation could increase the Aβ1-42 
production and the Aβ1-42 / Aβ1-40 ratio (approximately 2-fold), and the resulting Aβ1-42 peptide becomes 




, D7H-Aβ aggregates to form oligomers. Hence, D7H allele can be 
used to increase D7H-Aβ the production and aggregation [28,29]. H6R mutations increase the toxicity of all 
subtypes (isoform) and their rate of fiber formation. Due to the increase in Aβ dimers and C-terminal 
monomers, Aβ42 fiber forming time is shortened [30]. APP mutations not only can direct the Aβ generation 
(production), clearance (clearance), accumulation (accumulation), aggregation (aggregation) to influence 
the potential risk of AD, but also can increase the fat content of the body, indirectly enhancing the risk of 
AD [31]. 
APP imaging modalities:  changes of Aβ in brain atrophy 
A wide range of imaging modalities, such as MRI (Magnetic Resonance Imaging), functional MRI, 11C-
PiB (carbon 11-labeled Pittsburgh Compound B) PET (positron emission tomography) imaging have been 
utilized in supporting AD research [32,33]. In particular, some of these techniques enable the in situ 
detection and monitoring of senile plagues in AD patients [34]. These may provide evidence on the 
research of APP mutation and pathology evidence to enable the identification of the early signs of AD. 
Mutation of APP-E693Δ was found in cases of early FAD. The AD patients with the AD E693Δ mutation 
exhibit a memory dysfunction and partial brain atrophy. However, senile plaques are rarely seen, which 
may be due to low level of accumulation of Aβ in vivo [32]. According to 11C-labeled PiB-PET and 18F-FDG-
PET imaging, a significant difference between the Arctic APP (APParc) and Sweden (APPswe) mutations on 
APP has been observed [33]. APParc mutation carriers show low level of absorption of PiB in cortex, while 
the rate of glucose metabolism in the brain and the Aβ42 levels in cerebral spinal fluid (CSF) are low. 
APPswe mutation carriers absorbed more PiB in cortex, with the cerebral glucose metabolic rate reduced, 
which was especially obvious in the striatum. The Aβ42 level in CSF was increased significantly [33]. In 
contrast with the cerebro-absorption of 11C-PiB in sporadic AD patients, FAD with APP mutation carriers 
show large increases in absorption in striatum, posterior cingulate (caudate nucleus, putamen), while 
absorption in other cortical areas also show small increases [34]. In addition to the frontal lobe, the 
temporal lobe, occipital lobe and posterior cingulate cortex and other brain areas show increased 
absorption of 11C-PiB [35,36]. According to fMRI data, APP allelic variations can lead to increased activity 
in brain middle temporal gyri (MTG) and left fusiform gyri regions [37]. In summary, APP mutations may 
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affect the accumulation and deposition of Aβ and other cortical regions (see Fig. 3). This may also change 
the rate of glucose metabolism in the cerebral cortex and other regions of the striatum, resulting in an 
increased risk of synaptic dysfunction in AD patients. Further investigation will be required to understand 
the APP mutations and the exact mechanisms in regulating Aβ. 
 
Chromosome 19: (APOE) 
The effects of APOE on the clearance of Aβ: impacts of ε2, ε3, ε4 on Aβ 
The APP mutation mostly alters the generation of amyloid-β, which affects the AD pathogenesis. In 
marked contrast, the apolipoprotein E (Apo-E) in chromosome 19 works by clearing the amyloid-β to 
reduce the risk of AD.  If there is no mutation, Apo-E plays the role of clearing the soluble amyloid-β. With 
the aid of Apo-E, the activity of neprilysin is enhanced for the elimination of intracellular Aβ. In 
extracellular environment, the elimination of toxic Aβ is accomplished by Apo-E related insulin degrading 
enzymes. Thus, Apo-E isoforms can enhance the degradation of Aβ, while lipidated Apo-E can also be 
useful to accelerate the Aβ clearance [38]. 
Unlike Apo-E gene, Apo-E has three alleles ε2, ε3, ε4, which can promote the formation of hydrophobic 
Aβ and reduce the clearance of toxic Aβ, which increases the potential risk of AD [39]. APOE may be 
combined with hydrophobic ß-AP, which induces the formation of ß-AP monofilament and precipitation. 
Comparing with the allele ε3, ε4 forms a stronger bonding between the carrier protein Apo-E4 and ß-AP. In 
cases of the Apo-E ε4 homozygous individuals, the amount of ß-AP precipitation in brain is far more than 
that of the Apo-E ε3 gene homozygous individuals. In the ß-AP fibrous structure formation, Apo-E played 
an important role in the formation of senile plaques. 
For AD patients containing ε2, ε3, ε4 mixing genes in the brain, individuals with ε4 allele show higher 
incidence rate, while individuals with of ε2 allele show lower incidence rate [39-42]. For very elderly 
patients (90 years or more), Apo-E ε2 associated with intact cognition (dementia associated risk reduced). 
However, the increase in Apo-E ε2 associated with AD related neuropathology [40]. Autopsy on AD 
patients revealed that most of the Aβ peptide accumulation and precipitation genotypes are: Apo-E ε3/ε4 
(ε3/ε4 > ε3/ε3 > ε2/ε3). The Apo-E ε4 homozygotes carriers are generally dementia [41]. However, the age 
of AD diagnosed is negatively correlated with the risk of incidence.  Apo-E ε4 gene is related to the lowest 
age of AD diagnosed, while Apo-E ε2 gene is related to the highest age of AD diagnosed. For Apo-E ε3 gene, 
the age of AD diagnosed and the risk of incidence are between that of ε4 and ε2 [42]. 
Apo-E ε4 and other factors that affect AD 
It has been reported that the vast majority of AD patients (approximately 65% -75%) carry Apo-E ε4 
allele. The distribution of Apo-E allele varies among different races and geographical locations. Usually near 
the equator and in the Arctic region, populations carry higher frequency of Apo-E ε4 allele [43]. For the 
Chinese people, the risk of AD incidence with Apo-E ε4 allele was 3.93 times above average. In particular, 
ε4 homozygous genotype is a risk factor for AD; while Apo-E ε3 carriers show the risk of AD incidence 
lower than average [44]. Apo-E ε4 allele may also affect patient LOAD by reducing (approximately halved) 
the insulin-degrading enzyme (IDE) in the hippocampus. The main function of IDE is the degradation and 
removal of amyloid-β in the brain. The involvement of Apo-E ε4 and IDE in amyloid-β metabolism increases 
the risk of AD [45].  
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Before the onset AD (about 70 years), Apo-E allele and brain-derived neurotrophic factor (BDNF) lead to 
the brain's cognitive decline. In 4.5-year time, comparing to Aβ and ε4 noncarriers, Aβ/ε4 carriers showed 
significant cognitive decline, while individuals carrying Aβ without carrying ε4 show only vocabulary 
cognitive decline. In Aβ carriers (4.5-year later), comparing with the ε4 noncarriers, and ε4 / BDNFMet 
carriers (brain derived neurotrophic factor Met), the vocabulary and visual episodic memory decreased 
significantly faster.Regardless of the status of BDNF and Apo-E (4.5-year later), only little cognitive decline 
was observed in non-ε4 carriers [46].  
In the mice blood-brain barrier (BBB) model, it has been shown that Apo-E allele undermines the 
clearance of neurotoxic Aβ peptides (destructive effects: Apo-E4 is greater than that of the Apo-E3 and 
Apo-E2) [47]. In this context, Aβ peptides bind to Apo-E4, resulting in a rapid removal of free Aβ1-40 / Aβ1-42. 
The Apo-E4 inside the BBB can form complex with Aβ, which is significantly slower than that with LRP1 (LDL 
(low density lipoprotein) receptor-related protein 1). In contrast, the Apo-E2 and Apo-E3 on the BBB can 
form complex with Aβ in VLVLR (VLDL (very low density lipoprotein) receptor) and LRP1, where the 
clearance rate is faster than that of the Aβ-Apo-E4 complex [8].  The brain Apo-E allele offers different 
models of clearance for Aβ, which may help to understand the disease progression of AD in animal/human 
models.  
PET, MRI, DTI and fMRI imaging for Apo-E ε4 and their influences on brain networks 
As shown in Fig. 3, using the florbetapir (18F-FDG) positron emission tomography (PET) imaging 
technique, it has been shown that the APOE alleles in chromosome 19 and butyrylcholinesterase (BCHE) 
can be regarded as Aβ peptide deposition regulator [47]. In cognitively normal AD patients, the cortex 
glucose metabolism rate (CMRgI) is significantly reduced for Apo-E ε4 carrier [ε4 +], especially in the front 
frontal lobe, parietal lobe, temporal lobe and posterior cingulate regions [48-52].  
 
 
Figure 3. Schematic to shows the APP, APOE, PSEN mutations causing changes in the brain function. APP gene 
mutations resulted in the increase in the absorption of 11C-PiB in striatum, posterior cingulate gyrus (PCG), 
temporal gyrus (TG), occipital gyrus (OG), with the middle temporal gyri (MTG) and left fusiform gyri (FFG.L) 
activation increased. Apo-E ε4 allele mutations significantly reduced the superior frontal gyrus (SFG), parietal 
gyrus (PG), TG, PCG cortex glucose metabolism rate (CMRgI) and altered functional connectivity in brain 
regions including: PG, left SFG (SFG.L) and anterior cingulate gyri (ACG). PSEN1 gene mutation carriers showed 
significant increase in the absorption of PiB in striatum, ACG, PCG, thalamus and OG cortex. The axonal 
density increased in left thalamus (THA.L), striatum, hippocampus (HIP). Network characteristics changed 
including the default network connection, reduction of the SFG connections and increase in the inferior 
frontal gyrus (IFG) connections. The task state and the activation strength of LSFG and OG were reduced. 
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Apo-E ε4 dose is related with higher and earlier risk of dementia [50]. The hippocampal volume, the 
hippocampal glucose metabolism and posterior cingulate glucose metabolism are closely related to Apo-E 
[ε4 +] gene. Among these, the correlation of posterior cingulate glucose metabolism and Apo-E [ε4 +] allele 
is significantly greater than the correlation of hippocampal volume, glucose metabolism and Apo-E [ε4 +] 
allele [50]. 
MRI imaging has been used to study the cortical thickness in Vietnamese men. It has been shown that in 
the Apo-E homozygote-carriers [ε3 +] and the brain regions of Apo-E ε3/4 carriers, the frontal lobe, the left 
front and right rear volume central region are significantly thinner ; for Apo-E ε2/3 carriers, the right 
parahippocampal cortex region is relatively thick, which may be due to natural aging [53]. Diffusion tensor 
imaging (DTI) of T1 structure imaging revealed that Apo-E carrier [ε4 +] loss the interconnection faster than 
that due to aging, especially in the medial prefrontal orbital frontal cortex, precuneus and outer local 
parietal cortex region where the connectivity is reduced [54]. 
In a picture learning experiment using fMRI monitoring, Apo-E carriers [ε4 +] show enhanced BOLD 
signal during learning. This suggests that Apo-E4 allele in older adults with AD exhibit greater genetic risk 
with cognitive-related episodic memory [55]. There are significant functional connectivity changes in 
parietal lobe, left frontal regions and anterior cingulate [56, 57]. For Apo-E carriers [ε4 +], network 
connections were reduced in the left middle temporal gyrus, left parietal lobe, regional connectivity 
bilateral anterior temporal lobe, but were enhanced in  bilateral insular cortex, cingulate, connectivity 
striatum and thalamus medial prefrontal cortex [56]. 
During memory activation task, Apo-E carriers [ε4 +] show increased brain activation in the parietal 
lobe, left hippocampus and the prefrontal region. During the recall memory task, the signal density 
increases particularly in the hippocampus region with Apo-E carrier [ε4 +] greater than [ε3 +]. The average 
number of whole-brain activation area also increases [57]. Apo-E carrier [ε4 +] topology of the whole brain 
significantly impaired and the amount of parallel transmission of information reduced. Moreover the 
connections between the rear default mode network (p-DMN) and other brain functions were decreased. 
ECN，p-DMN and sensory-motor system also showed abnormalities and global topology damaged [58].  
Thus, Apo-E plays a role in the elimination of Aβ. With Apo-E genetic mutations, amyloid-β clearance is 
compromised, leading to Aβ accumulation. Regional, environmental, age and other factors could affect the 
Apo-E genetic mutations. Comparing with the Apo-E carrier [ε3 +], Apo-E carrier [ε4 +] is more likely to be 
an AD patient. 
Presenilin (PSEN) 
Mutations in PSEN, PSEN-1 and PSEN-2 
Presenilin (PSEN) is a transmembrane protein that functions as a part of the γ-secretase intramembrane 
protease complex. PSEN regulates protein transport and aberrant protein synthesis. Clearly, protein 
dysfunctions can affect βAPP, which could accelerate the development of AD [59,60].  In Presenilin-1 
(PSEN-1) gene and its homologous genes Presenilin-2(PSEN-2), the most common mutations occur in 
chromosome 14 and chromosome 1, which could lead to EOAD. However, the N141I mutation in the 
342/343 position of PSEN-2 is linked to EOAD and LOAD [61]. In transgenic mice model, it has been shown 
that PSEN-2/N141I mutation can reduce the Aβ40 level, but produce more neurotoxic Aβ42 leading to the 
Aβ1-42/Aβ1-40  ratio increases, and undermining the Aβ clearance [62]. 
The mutations in PSEN-2 mainly include: A85V, T122P, T122R, E126K, V148I, M174V, S175C, Q228L, 
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Y231C, M239I, M239V, T430M and D439A. These mutations could lead to EOAD [63-66]. Among these, 
T122R mutation modifies nerve fibers and M239 increases the production Aβ42 peptide, which are all 
dementia-related. Overexpression of PSEN-2 may promote Aβ42 fragments induced apoptosis [64,65]. For 
PSEN-1, mutation mainly changes the activity of γ-secretase thus enhancing the generation of Aβ peptides. 
The M146L, L166P and N141I mutations in PSEN-1 could lead to a functional impairment of γ-secretase, 
and inhibition of endogenous generation of Aβ1-40, leading to an increase of Aβ1-42 and  the Aβ1-42/Aβ1-40 
ratio [67-69]. 
The PSEN-1/G384A mutation is due to the accumulation of intracellular Aβ hydrolyzate (> Aβ1-42), which 
slows down the rate of degradation of Aβ in the cell membranes. After a long period of time, the Aβ 
hydrolyzate eventually degrades. Although this had no effect on the generation of Aβ1-42, the Aβ1-40 level 
was reduced [70]. In transgenic mice, heterozygous carriers with PSEN-1/R278I mutation express higher 
level of neurotoxic Aβ1-43 peptide, thus inhibiting the expression level of normal Aβ1-40 peptide. Embrynoic 
lethality was observed in homozygous carriers, indicating that the PSEN-1/R278I mutation could lead to 
physiological defects [71]. 
PSEN-1/I213T and PSEN1/C410Y mutations reduce the generation of Aβ1-40 and Aβ1-42 peptides [72,73], 
which is mainly due to the PSEN-1/I213T mutation destroys the APP C-terminal fragment of the cleavage γ-
sites. Thus, the total reaction rate γ-secretase is reduced, resulting in an increase of Aβ1-43, Aβ1-45 exceeding 
the Aβ1-46 production [72]. In PSEN-1 mutations, regardless of increase or decrease in the Aβ1-40 and Aβ1-42 
levels, the Aβ1-42/Aβ1-40 ratio always increases, resulting in neurotoxicity and increased risk of EOAD.  
6.2 PSEN-1 mutations affect the degradation of Aβ 
γ-secretase complex is one of key components for the hydrolysis of APP into Aβ peptides. In case of AD, 
PSEN-1 mutations significantly affect the activity of γ-secretase complex and alter AICD thereby increasing 
the Aβ1-42/Aβ1-40 ratio [74]. Through the use of γ-secretase, PSEN-1 FAD-linked mutations can degrade Aβ 
peptides, with the degradation pathways as follows:  
Aβ49 → Aβ46 → Aβ43 → Aβ40  
and  
Aβ48 → Aβ45 → Aβ42 → Aβ38  
This increases the neurotoxicity by increasing the Aβ1-42/Aβ1-40 residue [75]. Moreover, in vitro and cell 
internal PSEN / γ-secretase offer additional degradation pathway: Aβ43 → Aβ38.In contrast, the PSEN 
mutant acts on γ-secretase by inhibiting the degradation of longer Aβ. PSEN / γ-secretase can minimize the 
functional loss of Aβ42 and Aβ43, which could in turn help to prevent AD [76].  
Of course, the lower the toxicity of Aβ42 peptide and increase γ-secretase modulators (GSMS) can be 
fed back to the TMD-1 (transmembrane domain) of PSEN-1 to change its structure. In TMD-1 abnormal 
secretions include Aβ45 and longer Aβ peptides. TMD-1 helical surface comprises the binding function of 
Aβ45 and Aβ48. This combination changes the encoding mutations of the GSMS and TMD-1. At the same 
time, such a combination facilitates the formation of the hydrophobic Aβ42 [77]. 
PSEN-1 imaging study and regional shrinking effects 
With the aid of cerebrospinal fluid, plasma markers, structural MRI and fMRI studies, it is possible to 
assess the risk factors of EOAD in PSEN-1 autosomal mutations. In PSEN-1/E280A mutation carriers, it has 
been observed that the average age showing Aβ toxicity was 28, while the average age showing cognitive 
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impairment was 44 [78]. Klunk WE, et al. reported that in the PSEN-1/C410Y FAD-linked mutation carriers, 
striatal significant Aβ deposition has been observed in striatum, which led to cortical lesion. However, the 
lesion area is significantly smaller than that of sporadic AD patients [79].  
The use of 11C-PiB PET measurements further confirmed that the PSEN-1 striatal lesions were indeed 
caused by mutations. Compared with AD patients without PSEN-1, the striatum of the mutation carriers 
exhibited a considerably higher uptake of PiB. Beside, anterior cingulate, posterior cingulate, thalamus and 
occipital cortex cortical areas have also shown significant enhanced uptake of PiB [80]. In presymptomatic 
FAD, it has been shown that in PSEN-1 mutation carriers, the left thalamus and caudate nucleus shrank 
significantly. The density of axons, right hippocampus and right cingulate axon density were also reduced. 
In cases of FAD, axon density in hippocampus and caudate nucleus increase. This may be due to the 
intensive axonal lesion area further extending to the entire brain networks [81]. 
For PSEN-1 mutation carriers, a decrease in the glucose metabolic rate has been observed in PCC, 
bilaterally inferior parietal lobule, superior temporal gyrus, hippocampus and left entorhinal cortex regions 
[82]. When PSEN-1 mutation carriers undergo a visual coding task, resting-state fMRI shows the default 
network changes, which include a reduction in the number of connections in the frontal lobe, an increase 
in the number of connections at frontal rear increases. At the task state, the activation strength at the left 
prefrontal cortex and occipital are reduced, while posterior cingulate and precuneus activation are 
enhanced (see Fig. 3) [83]. 
Conclusion 
Overall, the gene mutations in chromosome 21, 19, 14 and 1 in the context of AD are less than 30 %. 
More genetic risk factors leading to AD have yet to be discovered [5]. Currently, chromosome 12, 10 and 9 
are found to be genetically related to AD. Chromosome 10 mutations increased intracellular Aβ1-42 peptides 
and plasma Aβ. Chromosome 10 and 12 mutations also increased the risk of FAD-linked LOAD [84-85]. 
Finally, research in AD pathology and function in the context of genetics will continue to enhance our 
understanding of the pathogenesis of AD and the formation of senile plaques. Through the regulations of 
α-, β- and γ-secretases, it may be possible to help restoring the homeostasis of Aβ, which could prevent 
and/or reduce the incidence of AD. 
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